1 clized peptides, a resemblance heightened by
heterologous prime-boost.
2 s in successive immunization campaigns or as
heterologous prime-boost agents.
3 y of these constructs was evaluated using a "
heterologous prime-boost"
approach consisting of mucosal
4 Completing the serial immunization steps for
heterologous prime-boost-
boost can be lengthy, leaving t
5 Heterologous prime-boost-
boost immunization has been sho
6 These results suggest that
heterologous prime-boost combinations have distinct immu
7 sing vaccines against bovine TB are based on
heterologous prime-boost combinations that include BCG,
8 Heterologous prime-boosting has emerged as a powerful va
9 Here, we used a
heterologous prime-boost immunization approach using a c
10 Such
heterologous prime-boost immunization approaches may pro
11 AdCh63-MVA
heterologous prime-boost immunization induces strong and
12 Heterologous prime-boost immunization strategies can evo
13 We also describe homologous and
heterologous prime-boost immunization strategies using n
14 vel vaccine were assessed in mice by using a
heterologous prime-boost immunization strategy and compa
15 Heterologous prime-boost immunization with plasmid DNA a
16 re examined by using multiple homologous and
heterologous prime/boost immunization regimens in order
17 The
heterologous prime/boost immunization regimens that invo
18 ntrast, Mamu-A*01+ monkeys that had received
heterologous prime/boost immunizations prior to challeng
19 ors, the possibility has arisen of employing
heterologous prime/boost immunizations using diverse mem
20 Recent clinical trials of new
heterologous prime-boost malaria vaccine regimens using
21 Heterologous prime-boost may provide a more effective va
22 a single immunization or in a homologous or
heterologous prime-boost modality.
23 s shown that vaccination strategies based on
heterologous prime-boost protocols using Mycobacterium b
24 ChAd63-MVA AMA1 administered in a
heterologous prime-boost regime was shown to be safe and
25 used to vaccinate rhesus macaques with a new
heterologous prime-boost regimen designed to optimize in
26 These vectors, when used in a
heterologous prime-boost regimen in BALB/c mice, are cap
27 In contrast, an accelerated
heterologous prime-boost regimen involving administratio
28 hrocytic vaccine will likely be based upon a
heterologous prime-boost regimen that induces both appro
29 ted its immunogenicity early in life using a
heterologous prime-boost regimen.
30 In this study, we show that such
heterologous prime boost regimens based on E1-deleted ad
31 rime AIDS virus-specific T-cell responses in
heterologous prime boost regimens.
32 Thus,
heterologous prime-boost regimens boost CD4(+) as well a
33 Moreover, anatomic separation strategies and
heterologous prime-boost regimens generated codominant r
34 his study supports the rationale for testing
heterologous prime-boost regimens in humans.
35 to evaluate the safety and immunogenicity of
heterologous prime-boost regimens, with a New York vacci
36 3-specific CTLs can, however, be expanded by
heterologous prime-boost regimens.
37 serotype Ad vectors than with Ad5 vectors in
heterologous prime-boost regimens.
38 nses when administered with rVSVN4CT1gag1 in
heterologous prime-boost regimens.
39 f cytotoxic-T-lymphocyte responses have been
heterologous prime/boost regimens employing a plasmid DN
40 Heterologous prime/boost regimens have the potential for
41 Heterologous "prime-boost"
regimens that involve priming
42 future clinical trials testing vector-based
heterologous prime-boost strategies.
43 nds in vaccination strategies, particularly "
heterologous prime-boost"
strategies against tumors, and
44 ed MV vaccines to be used early in life in a
heterologous prime-boost strategy.
45 aepithelial neoplasia were vaccinated with a
heterologous prime/boost strategy consisting of gene gun
46 the current live attenuated MV vaccine in a
heterologous prime-boost to protect against measles earl
47 Heterologous prime boost vaccination minimizes contracti
48 This study exploited
heterologous prime boost vaccination to discover paramet
49 Heterologous prime-boost vaccination has been shown to b
50 Only
heterologous prime-boost vaccination induced modest cros
51 Here we show that a
heterologous prime-boost vaccination regime of DNA eithe
52 These results suggest that
heterologous prime-boost vaccination regimens enhance im
53 Heterologous prime-boost vaccination results in increase
54 In this study, we employed a
heterologous prime-boost vaccination strategy comprising
55 This study reports the efficacy of a
heterologous prime-boost vaccination using DNA and vacci
56 We explored the concept of
heterologous prime/boost vaccination using 2 therapeutic
57 The
heterologous prime-boost vaccine regimen used recombinan
58 Heterologous prime-boost vaccine regimens induced partic
59 Our results demonstrate that
heterologous prime-boost vaccine regimens with alternati
60 rhesus monkeys and can be combined as potent
heterologous prime-boost vaccine regimens.
61 ChAd63-MVA is a promising
heterologous prime-boost vaccine strategy that could be
62 at CD4(+) and CD8(+) T cell responses with a
heterologous prime/boost vaccine approach could induce l
63 Heterologous prime-boost with the viral vectors simian a
64 Heterologous prime/boost with Cy/GVAX and CRS-207 extend